Akari Therapeutics plc ADR (0.01 USD) earnings per share and revenue
On 13 de nov. de 2025, AKTX reported earnings of 0.00 USD per share (EPS) for Q3 25, beating the estimate of -0.07 USD, resulting in a 100.00% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +1.67% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analistas forecast an EPS of -0.06 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and aumentar of 0.00% in Revenue from the last quarter.
FAQ
What were Akari Therapeutics plc ADR (0.01 USD)'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Akari Therapeutics plc ADR (0.01 USD) reported EPS of $0.00, beating estimates by 100%, and revenue of $0.00, 0% as expectations.
How did the market react to Akari Therapeutics plc ADR (0.01 USD)'s Q3 2025 earnings?
The stock price moved up 1.67%, changed from $0.52 before the earnings release to $0.53 the day after.
When is Akari Therapeutics plc ADR (0.01 USD) expected to report next?
The next earning report is scheduled for 13 de abr. de 2026.
What are the forecasts for Akari Therapeutics plc ADR (0.01 USD)'s next earnings report?
Based on 5
analistas, Akari Therapeutics plc ADR (0.01 USD) is expected to report EPS of -$0.06 and revenue of -- for Q4 2025.